{"id":"NCT02918279","sponsor":"Novo Nordisk A/S","briefTitle":"Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity","officialTitle":"Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-29","primaryCompletion":"2019-02-14","completion":"2019-08-08","firstPosted":"2016-09-28","resultsPosted":"2020-04-27","lastUpdate":"2020-04-27"},"enrollment":251,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"interventions":[{"type":"DRUG","name":"Liraglutide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Liraglutide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.","primaryOutcome":{"measure":"Change in BMI SDS (Week 0, Week 56)","timeFrame":"Week 0, week 56","effectByArm":[{"arm":"Liraglutide 3.0 mg","deltaMin":-0.25,"sd":0.51},{"arm":"Placebo","deltaMin":-0.02,"sd":0.54}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0022"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":33,"countries":["United States","Belgium","Mexico","Russia","Sweden"]},"refs":{"pmids":["32233338","37264767"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":125},"commonTop":["Nasopharyngitis","Nausea","Headache","Vomiting","Diarrhoea"]}}